MDACC Study No:2013-0315 ( NCT No: NCT01889186)
Title:A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with
Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
Principal Investigator:William G. Wierda
Treatment Agent:ABT-199
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ABT-199 can help to
control CLL in patients who have an abnormal gene called a 17p deletion and
its safety. The tolerability of ABT-199 will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:ABT-199
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:AbbVie
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults